Legal Representation
Attorney
David S. Kerr
USPTO Deadlines
Next Deadline
52 days remaining
Notice of Allowance Mailed - SOU Required
Due Date
September 25, 2025
Extension Available
Until March 25, 2026
Application History
12 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 2, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jul 1, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 28, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 28, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 25, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 28, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 28, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 22, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 7, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 18, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 17, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 5, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 044
Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of persons, namely, namely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of a major depression disorder; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers for medical purposes; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for major depressive disorders (MDD); Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for predicting patient response to selective serotonin reuptake inhibitor (SSRI) and disease prognosis based on SSRI treatment; and Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for predicting patient response to SSRI for treatment of major depressive disorder (MDD) and predicting disease prognosis following treatment
First Use Anywhere:
Nov 1, 2024
First Use in Commerce:
Nov 1, 2024
Additional Information
Pseudo Mark
MIND LIGHT
Classification
International Classes
044